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Abstract
Inventory management is a complex aspect of Supply Chain Management that is
frequently discussed and debated due to the fact that it has a high impact on customer
satisfaction as well as financial performance. This thesis addresses how an inventory
management policy was developed and established in a vaccines company where
customer service is the top priority and product quantities are high.
The work in this thesis is from a six month internship at Novartis Vaccines and
Diagnostics in Marburg, Germany. Project work focused on three inventory management
questions: What are the right inventory targets for each product? What is the process to
manage, monitor and maintain the inventory targets? How should the inventory targets be
measured and controlled?
The results from this project show that an effective way to set inventory targets is through
the combination of analytical inventory calculations and the strategic analysis of the
business environment. A detailed inventory model was built in Microsoft Excel that uses
common inventory formulas and considers critical product attributes such as shelf-life,
process lead times, batch sizing, replenishment frequency and capacity constraints to
calculate the inventory targets. The model results are part of the larger inventory
management policy that was created and incorporated into the Supply Chain group's
Sales & Operations Planning process. The complete inventory management policy
addresses the details of regularly setting inventory targets, how they should be
maintained and tracked and defines clear roles and responsibilities.
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1 Introduction & Background
"Keeping healthy people healthy" is one of the mottos heard throughout the
Novartis Vaccines and Diagnostics organization. The mission to deliver vaccines that
prevent the contraction and spread of serious diseases is one that Novartis employees
proudly support. Ensuring that the right amount of each vaccine is available when and
where needed is one of the most important aspects of guaranteeing that the company
goals are achieved. The challenge of delivering vaccines to diverse international markets
with varying requirements is not to be overlooked. As a result, the supply chain strategies
for vaccines can be extremely complex.
Within Novartis Vaccines and Diagnostics, the customer is number one. Since
shortage of even a single dose of a vaccine could have a large social impact, it is to be
avoided at all costs. This focus drives high customer service levels and means that
Novartis Vaccines and Diagnostics has taken a conservative approach with inventory
levels to ensure that they can meet their customer needs and avoid shortages and stock-
outs. This results in high inventory levels, large amounts of obsolete material and
unnecessary costs. As Novartis Vaccines and Diagnostics grows, it must (like any
organization in a growth period) evaluate current operations strategies to determine what
the right strategy is for setting and managing inventory levels in a highly customer
service oriented organization.
1.1 Novartis Company Overview
Novartis Group is headquartered in Basel, Switzerland, and employs
approximately 98,000 full time employees who work in over 140 countries around the
world (About Novartis, 2009). Novartis is one of the leading international pharmaceutical
companies and provides a diverse portfolio of products to meet various needs such as:
innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines,
diagnostic tools and consumer health products. Within the Novartis Group there are four
divisions that have been set up to help develop and manufacture the products that meet
these needs (Novartis Businesses, 2009):
1. Pharmaceuticals: Innovative patent-protected medicines
2. Vaccines and Diagnostics: Human vaccines and diagnostic tools to protect
against life-threatening diseases
3. Sandoz: Generic pharmaceuticals that replace branded medicines after patent
expiry and free up funds for innovative medicines
4. Consumer Health: Readily available products that enable healthy lifestyle
choices: OTC (Over-the-Counter), Animal Health and CIBA Vision.
1.1.1 Novartis Vaccines and Diagnostics
The Novartis Vaccines and Diagnostics division focuses on developing human
vaccines and diagnostic tools to protect against life-threatening diseases. The division has
two businesses: Novartis Vaccines and Chiron. Novartis Vaccines, where the scope of
this thesis is focused, is the world's fifth-largest vaccines manufacturer and second-
largest supplier of flu vaccines in the US. The division's products vary from seasonal flu
vaccines to meningococcal, pediatric and travel vaccines. Chiron, the blood testing and
molecular diagnostics business, is dedicated to preventing the spread of infectious
diseases through the development of novel blood-screening tools that protect the world's
blood supply (About Novartis Vaccines & Diagnostics, 2009).
Novartis Vaccines was established in April 2006, following the acquisition of
Chiron. Today, Novartis Vaccines maintains a strong global presence (see Figure 1 for a
world map of locations) with centers of excellence in Germany, Italy and the United
Kingdom. Expansion is also in the near future for Novartis Vaccines; a United States site
in Holly Springs, North Carolina is being built to provide the US market with influenza
vaccines and protect against demand spikes that result from future pandemic
environments. In addition to existing manufacturing sites across the world, Novartis'
global presence also includes their customers. Vaccine deliveries span the globe from
Greenland to Antarctica and nearly everywhere in between.
Cambridge
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Figure 1: Novartis Vaccines and Diagnostics Global Presence
1.2 Problem Motivation
Since the acquisition of Chiron is still in the recent past of the division, Novartis
Vaccines is in the process of developing a culture and identity to ensure their position as
an industry leader. A large part of establishing this identify involves creating standard
policies and best practices for major business processes. As the Novartis sites across the
world try to work together to achieve their business goals, many inconsistencies are
uncovered and opportunities for improvement are realized. With customer service being
one of the highest priorities for Novartis Vaccines, ensuring that inventory levels are set
appropriately to meet demand is extremely important and is an area that needs not just
consistency across sites, but also formal policies.
1.2.1 Supply Chain at Novartis Vaccines
The Global Supply Chain group within Novartis Vaccines ensures continuous
flow of products to customers from the moment of the initial sales order, through
production planning and execution, to final delivery at the customer location. For all
products, the customer service level goal is 98% of product delivered on time and in full.
The Supply Chain group operates under a formal Sales & Operations Planning (S&OP)
............
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process, which ensures customer demand for the next 18 months is supported with
manufacturing plans that will deliver the right product, in the right quantities, to the
customer on the required date. (Global Supply Chain Website, 2009)
1.2.2 The Specific Inventory Problem
Material within the Novartis Vaccines supply chain travels through four different
stages before reaching completion:
1. Concentrate Material is the active material used during both the conjugation
and formulation process.
2. Bulk Material is material that has completed the manufacturing formulation
process and is typically stored in 75 liter steel containers while it waits for
filling and packaging.*
3. Semi-Finished Material has gone through no formulation changes, but has
been transferred from the 75 liter steel containers into either a syringe or vial
based on customer requirements for packaging.
4. Finished Goods are achieved when the semi-finished material is combined
with a product information leaflet and the proper box for packaging. Once
material is in this state, it is typically stored in a warehouse until it is
necessary to deliver to a customer.
Figure 2 shows the standard supply chain process that a vaccine follows.
* In some cases, Bulk Material is used as Finished Goods. This occurs when customers do not require
Novartis Vaccines to deliver the product in a filled and packaged form. In this case, the bulk material is
transferred from the large 75 liter steel containers to smaller 20 liter glass containers for delivery to the
customer.
Figure 2: Supply Chain Diagram for a Vaccine
Variations from the standard supply chain described above can occur at any stage
of the supply chain since each product will follow the path through the supply chain a
little bit differently. To add to this complication, the path followed varies not just by
product, but also by customer destination. This requires that care be taken when
inventory levels are set as a standard method cannot be applied to every single item.
With high customer service level requirements, Novartis Vaccines has historically
chose to carry inventory to serve anywhere between six months and two years demand
(this number is selected relatively arbitrarily) to ensure that coverage is available. While
this strategy does provide high customer satisfaction, it causes other business issues, such
as high obsolete material, and does not consider different strategies for holding inventory
at various stages throughout the supply chain.
The need for a formal policy is important not just for developing common
standards and processes across the site, but also to establish control and monitoring
mechanisms for management to make strategic decisions about manufacturing levels and
delivery commitments.
1.3 Hypothesis
This thesis explores different methods to implement a formal inventory
management policy in a highly customer focused environment and with hundreds of
Stock Keeping Units (SKUs).
A policy of aggregating similar products is analyzed and it is hypothesized that
using natural groupings of similar products is the most efficient way to set inventory level
policies versus having a separate policy for each SKU.
The final policy will need to provide both an analytical solution and consider non-
tangible factors to ensure that the critical attributes of each product grouping are
appropriately evaluated.
1.4 Thesis Organization
There are seven chapters contained in this thesis. Chapter 1 discusses the
company background and framing of the inventory management problem. Chapter 2
explores the current state of inventory management across all of the sites to identify
challenges that may occur with future changes as well as to unveil best practices that
could be carried across all locations. In Chapter 3, the approach used to develop the
inventory model and policies is shared in detail. Beginning in Chapter 4, the details of
the model are described as well as the special considerations that are used to ensure the
model is customizable for the supply chain nuances at Novartis Vaccines. Chapter 5
discusses how the model was incorporated into the Novartis Vaccines organizational
processes to ensure sustainability after the completion of this thesis work. Chapter 6
provides three case studies that share how the model successfully tackles different
inventory management problems. Finally, Chapter 7 summarizes the key findings from
the model development and policy setting processes as well as discusses opportunities to
further refine and improve the work done in this thesis.
2 Current State Observations
Understanding the current operating procedures is one of the most important steps
when trying to establish new processes. There are often assumptions and constraints that
drive the current business and need to be understood in order to effectively manage any
future change or new process. In the case of Novartis Vaccines, gaining this
understanding is challenging because there are three main manufacturing sites across
Europe, (England, Germany and Italy) which are responsible for different products, as
shown in Figure 3, and therefore each operates with different methods and process.
Marburg, Germany
Products: Flu, Rabies, Tetanus
Tick Borne Encephalitis
Facilities: Bulk Manufacturing
Paaivrolngln
PackgingRosia, ftaly
Products: Flu, Meningitis, Polio
Facilities: Bulk Manufacturing,
Filling and Packaging
Figure 3: European Manufacturing Sites
This chapter explores the processes observed at each of the manufacturing sites,
discusses what is going well, suggestions for improvement, and addresses potential areas
of focus to ensure successful future change.
2.1 Sales & Operations Planning Process
Among all sites, inventory management occurs primarily through the SAP
materials resource planning system; however, Microsoft Excel spreadsheets are
* There is a fourth vaccine manufacturing site in India that produces only one product for India; it is a joint
manufacturing venture. There is also a fifth manufacturing site in Holly Springs, North Carolina, which
was still being built at the time of this thesis. Neither site is included in the scope of this thesis.
................................ ...
frequently used by personnel to track information that is either not available or has not
been fully integrated into SAP. The role of inventory management crosses various
departments within Novartis Vaccines and is defined within the Sales & Operations
Planning (S&OP) procedures which clearly identify the responsibilities for all key
players.
There are two primary organizations that drive the S&OP process: Commercial
Supply Chain (CSC) and Production Logistics (PL). CSC is a team of individuals who
are the liaisons between the customers, both private and public, and with production
logistics. The CSC group is responsible for forecasting product demand in a specific
customer area and providing that information to PL in order to allow proper coordination
with manufacturing to meet demand requirements. PL is responsible for the process of
ensuring that production teams can meet customer demand as forecasted by CSC. PL uses
the customer orders to forecast supply and create production plans for each of the
individual manufacturing sites. These activities occur every month within the framework
of the four phases in the S&OP process:
1. Demand Phase: During the demand phase, the 18 month rolling forecast
(RFC) is updated by Commercial Supply Chain. The new RFC is then
uploaded into SAP to be used for the next phase.
2. Supply Phase: Once the new demand has been updated in SAP, Production
Logistics will work with manufacturing at each site to develop detailed supply
plans that identify potential supply constraints and confirm manufacturing's
ability to meet the customer requirements.
3. Global S&OP Meeting Phase: When the individual sites have completed their
supply plans, they are consolidated into a single S&OP presentation that is
reviewed by Global Supply Chain management to address issues and receive
approval to move ahead with production plans. Any issues not approved are
escalated to the final phase.
4. Executive S&OP Phase: The final phase of the S&OP process is when issues
that were not able to be resolved in the Global S&OP process are brought to
the executive committee for their review and decision. The executive
committee will make final decisions during this phase that are then
incorporated into either the demand or supply plan, where applicable.
Another important aspect of the S&OP process is the three month frozen period,
which dictates that no changes are made to the demand forecast for the current month
plus the next three future months. If changes occur during this period, a high level of
coordination among manufacturing and production logistics is necessary to ensure that
the new demand can be fulfilled.
2.1.1 Demand Forecasting
The forecasting process within Novartis Vaccines, while identified clearly within
the S&OP, is the most challenging process for many personnel within Supply Chain.
As discussed earlier, demand forecasts are developed by the Commercial Supply
Chain group and are updated on a monthly basis during the S&OP process. Commercial
managers (some by site, some by product) are responsible for providing their sales
forecast to a single point of contact who integrates each individual demand into a single
Microsoft Excel file. In order to develop these forecasts, each commercial manager must
rely on their own knowledge about their area of responsibility to estimate future sales.
This leads to forecasts which have minimal formal forecasting methods integrated into
the final numbers that are input into SAP.
The result is highly volatile demand numbers that the Production Logistics group
often questions. Additionally, since a formal tool to track demand forecast accuracy does
not exist, there is no data to indicate what type of variability may occur when Production
Logistics is creating supply plans.
This uncertainty makes the ultimate goal of achieving high customer service
levels even more challenging. In order to successfully manage inventory levels, it is
critical to have not only a solid demand forecasting process that all team members
support and understand, but also a measure of process accuracy.
2.1.2 Value Stream Process Flows
SAP has the ability to manage much of the data related to the value stream
process, including lead times and processing times. In the case of the vaccines process
flow at Novartis, each product follows a slightly different path based on where each step
in the manufacturing process occurs. Identifying this process flow is challenging;
however, it is a critical first step to setting up an inventory process. Table 1 (below)
shows a sample of how each product group was documented.
Group A Rosia Rosia Rosia Rosia Rosia
Group B Rosia Rosia N/A N/A Rosia
Group C Marburg Marburg Third Party Third Party Marburg
Group D Marburg Marburg Third Party Third Party Marburg
Group E Marburg Marburg N/A N/A Marburg
Group F Licensed Licensed Licensed Licensed Third Party'
Table 1: Sample of Table Used to Identify Process Locations
Once the physical locations of each manufacturing step are understood, it is
necessary to associate durations with each process step. While the ideal situation is for
the data to be in a system such as SAP for automatic download, the reality is that this
does not exist in many organizations, including at Novartis. At Novartis, lead time and
process duration data exists in various forms, including: SAP, Excel Spreadsheets, Value
Stream Maps, and the brains of the subject matter experts.
Table 2 provides a brief summary of where critical pieces of data exist within in
Novartis Vaccines.
* This is a third party supplier that provides filling and packaging services for Novartis Vaccines. Their
services are typically used only for products built by the Marburg, Germany facility during for seasonal
production.
t This third party supplier provides warehousing space to store vaccine products which are produced by all
European sites; however, are distributed only within the country of Germany.
Primary manufacturing Excel Spreadsheets, Value Stream Maps, SAP
Transportation times Third Party Logistics Provider database
Secondary manufacturing Excel Spreadsheets, Value Stream Map
Quality release approvals Value Stream Maps, Subject Matter Experts
Delivery times to customer Third Party Logistics Provider database
Table 2: Data Sources for Process Flow Durations
Adding to the complexity of understanding process times is the uncertainty that
exists about how and when a process step will be completed. There are three critical
process steps which have a high level of uncertainty:
* Scheduling the filling and packing operations time. Filling and packing
operations exist only at some of the manufacturing sites, therefore, some
product's filling and packaging schedules need to be managed by Production
Logistics personnel at multiple manufacturing sites. This is a challenge, not
just because of the distance, but also because capacity constraints exist
throughout the year and are even more prominent when flu vaccines are being
packaged.
" Quality release waiting times. All of the vaccines must be approved before
final release to the customer and sometimes to proceed through the next stage
in the manufacturing process. While there are committed durations for this
process, there is no guarantee that these times hold for any individual batch.
Additionally, when time is critical, it is often possible to expedite these times
in order to move more quickly through the process.
* Yield variation resulting from the manufacturing process. When
formulating a vaccine, the yield that results from the chemical process will
vary for every batch. This process variation means that the doses that result
from each batch are not consistent. This uncertainty is known by
manufacturing and taken into consideration when planning batches to meet
customer demand.
For the purposes of this analysis, standard lead time values were used for all calculations
since the data was not available to determine the process variation.
2.1.3 Transportation and Warehousing
Transportation methods at Novartis Vaccines are very different for each product.
The coordination of material movement within the Novartis supply chain is complex due
to location, quantity and quality requirements. As mentioned earlier, a single product
could follow dozens of different paths depending on the final customer and the product
packaging. An item can be stored within many different warehouses throughout its
manufacturing life and this is no different for the Finished Goods stage. Often, once
complete, a product will go to a Novartis owned warehouse for a short time before
requiring the necessary coordination to distribute it to specific countries and customers,
potentially even being sent to an intermediate warehouse location before final delivery.
Warehouse storage is also complex; capacity limitations and locations of
warehouses increase the complication of producing and holding inventory. A
conservative approach of holding large amounts of inventory has protected the company
from unforeseen demand uncertainty; however, product in various stages is stored at
approved external locations due to the internal warehouses often being at 100% capacity
at peak times. Additionally, operating for an extended period of time at maximum
capacity does not allow flexibility as there is no margin for error or movement.
Being able to properly set and manage inventory levels will have a positive
impact on the current challenges faced within the Distribution Logistics organization
because it will allow them to plan for the future and have foresight into problems that
could be faced due to changing inventory levels with certain products.
2.1.4 Finance: Inventory Accruals and Valuation
With millions of doses of inventory being held across the Novartis Vaccines sites,
it is important to track and understand the total value of inventory. The Finance group
holds the responsibility for this task, including documenting current inventory amounts,
processing accruals for inventory that has expired or is lost due to poor quality, and
coordinating inventory destruction.
The second task of Finance that is related to inventory management is managing
and monitoring the actual costs associated with materials. There are two types of costs
that exist for materials and that are tracked in SAP:
e Standard Prices are used for goods received from a supplier. Examples of
this are packaging materials such as syringes or leaflets, and raw materials
such as chemicals used in the manufacturing process.
" Moving Average Prices are associated with materials that progress through
the manufacturing process. The moving average price is updated regularly
when a new batch is produced and new actual data is entered into SAP. When
this occurs, the difference between the expected costs and the actual costs are
evaluated. For a positive difference between these numbers (when the actual
costs are higher than expected), the moving average price will increase,
because actual product yield was worse than expected. The reverse occurs
when a negative difference results.
The appropriate price is used by Finance to declare the value of inventory in the Profit
and Loss statement as well as to accrue product write-offs.
While the interaction between these organizations occurs slightly differently at
each site; regular communication occurs and consistent process are being followed.
2.1.5 Metrics
Being able to track and monitor inventory level data is a critical aspect to ensuring
the success of setting up a new inventory policy. When this project initiated at Novartis,
there were no routine reports being prepared and reviewed for inventory levels across the
whole value chain (specific site / section reports were prepared to assist in detailed
planning activities). As a result, when questions were asked about inventory levels, a
member of the Production Logistics team would need to begin a specific effort to look up
all of the needed data before being able to give results to the requester.
During the time of this project, an add-on to SAP, Business Warehouse, was
introduced and offered a method to compile demand, supply and inventory data in a
single chart for each product. This new tool provides a forecast of inventory levels given
the current forecasted demand numbers. Unfortunately, the tool lacks flexibility for data
manipulation and chart design and could not always provide the inventory data needed.
Having a useful metric to monitor and control information is necessary in order to
be successful when trying to increase the awareness of and performance in any area.
Seeing the weakness in this area highlighted the importance of having a formal inventory
policy that not only provides inventory targets, but also creates a foundation to control
inventory levels.
2.2 Organizational Assessment
After gaining insight into the critical business processes related to inventory
management, it became evident that in order to successfully implement a new policy into
the Supply Chain Organization, the environment must be considered. Implementing a
new policy with new measurement methods is not usually met with open arms; however,
in a young organization like Novartis Vaccines, the opportunity exists to do it right. In
order to do this, special consideration was taken to understand the current organizational
environment.
The Sloan School of Management at the Massachusetts Institute of Technology,
developed a process for evaluating organizations called the Three Lens Analysis (Carroll,
2006). This analysis looks at three areas (lenses) to identify challenges that an
organization could face while undergoing change. This analysis was used to understand
the risks associated with implementing the new inventory policy.
2.2.1 Strategic Design Lens
The strategic design lens evaluates the formal structure and strategy of the
organization to understand if there are any structural conflicts that could prevent project
success.
Within the Supply Chain organization, the strategy of the organization is that
customer service is priority number one. During the observation phase of the project, this
motto was emphasized repeatedly and, it became clear that the costs associated with
carrying extra inventory are not critical compared to guaranteeing that demand requests
will always be met.
The Supply Chain group is progressive and management is supportive of change.
The current environment is one where new and improved policies are constantly being
established to provide better guidance for the current organizational processes. Therefore,
implementing a new policy is not something that is unusual at this point in time.
However, this project spans multiple organizations. Therefore, even though Supply Chain
is responsible for setting and managing the policy, other organizations must be aware of
it and be willing to support the same goals and changes.
While implementing this new process does not require any structural changes for
successful implementation, it is important that all organizations are supportive and
understanding of why new measurements and methods will be put in place. Additionally,
the new process does mean that there are new roles for the Supply Chain team members.
Therefore, it will be important to ensure that the final policy includes a method for
communication and coordination among all of the groups who have responsibility for
setting and managing inventory levels.
2.2.2 Political Lens
The political lens considers the different interests and goals that guide individuals,
groups, and departments and how those interests might disrupt the intent of the project.
Fortunately, the key stakeholders in the Supply Chain group are supportive of
establishing a formal policy and see it as something that is aligned with their own goals.
A source of political conflict may exist among the different departments because each
group has a different aspect of the process that they feel deserves extra time and
consideration. While the ideas brought up by these groups are often relevant and
important to the overall success of Novartis, they could not always be incorporated
directly into establishing an inventory management policy. As a result, when these types
of items were identified, they were documented and many of them either were
incorporated either into the formal policy document written for Novartis or are found in
Chapter 7 where opportunities for future work to improve the project results are
discussed.
This project does have some additional political impact because the Director of
the Technical Operations organization is frequently interested in product inventory levels
and strongly supports having a formal policy developed. Having this high level of power
encouraging the project forward is a good thing; however, it is important that it does not
become the justification for the change and is instead the motivator for finding the best
and right way to complete the work.
2.2.3 Cultural Lens
The cultural lens looks at how a change could challenge the cultural norms and
values that exist within the organization; thus increasing the risk of successfully
implementing a new process.
Because of the diverse countries that NV&D operates in, this may be the most
critical lens to understand. It is important to identify the different cultural norms, values
and basic assumptions that could conflict with the goals of the project.
One of the primary risks seen is that many individuals believe the transition to
create more common processes is a threat to their uniqueness and value. Employees at
each site frequently emphasized that their products were different than the other sites and
that special consideration was needed. Knowing that individuals felt this way, it became
very important to ensure that a final policy offered formality but with enough flexibility
that all parties feel their products fit into the framework.
2.3 Chapter Summary
Throughout this chapter, the supply chain processes were discussed, including
specifically how they impact decisions related to inventory management. Additionally,
three aspects of the organizational environment were explored: cultural, strategic and
political. Within the future chapters of this thesis, discussion will continue on how a
formal inventory policy is implemented while considering these current business
processes and without significantly disrupting the organization's environment.
3 Approach
Once the framework of the problem and the current state of the environment are
understood, the discussion about how to develop a solution that fits a given organization
begins. This chapter explains the approach used to apply general inventory theories and
methodologies to a unique set of organizational and process characteristics.
3.1 General Approach
With the ultimate goal to create a formal policy for management of the inventory
for all products at Novartis Vaccines, it became critical to understand the unique
characteristics of each product in order to ensure that the final policy could provide useful
results for each product. As discussions progressed, it became clear that this could not be
achieved with only a mathematical inventory model; but needed to also include a
decision process that evaluated a product based on its' unique business characteristics.
The combination of these two analyses leads to a complete inventory policy with targets
for each product that considers all critical inputs; this approach is shown visually in
Figure 4.
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Figure 4: Two Step Approach to Develop Inventory Targets
3.2 Step 1: Evaluate the Business Characteristics
In this step of the model, an individual product is analyzed based on known
business characteristics and their impact on the manufacturing of the product. This
portion of the analysis is relatively subjective; the results rely on knowledge of all current
and future business plans as well as a consistent perception of the impact the interruptions
or changes will have on the need to hold inventory for a given product.
3.2.1 Step 1 Model Inputs: Information Sharing
To complete this portion of the analysis, no numerical data inputs are needed.
Instead, all personnel who support the product must provide input related to the future
manufacturing plan for that product. Questions that need to be answered include:
" What manufacturing stages does this product move through?
e Are there any shelf-life limitations that prevent holding inventory at certain
process stages?
e Is the product critical or life saving?
* Is there any known future manufacturing interruptions?
* Is a large amount of demand expected during a time when capacity is limited?
* Are any of the processes extremely unstable?
Appendix 1 shows an image of the user input section of the model that needs to be
completed with this information.
3.3 Step 2: Run the Analytical Model
The second step in the process is the analytical model. The analytical model is
more complicated than the business characteristics analysis in Step 1 because it requires
complete understanding of the manufacturing process, as well as the collection of all of
the raw data needed to perform the analytical calculations. A sample of the Step 2 user
input sheet can be found in Appendix 2.
3.3.1 Step 2 Model Inputs: Data Collection & Analysis
Gathering the data needed for an analytical model is often the most difficult part
of developing a model because the data usually does not exist in the format or level of
detail that is required. Additionally, even when the data does exist and is gathered,
deciphering its meaning and transferring it into a compatible format to support the model
can be a complex project in itself. For the development of the NV&D inventory model,
there are three main areas for which data needs to be collected and analyzed: demand
forecast accuracy, process lead times and material value at each stage of the process.
3.3.1.1 Demand Forecast Accuracy
Understanding the accuracy of the demand forecast is critical when setting
inventory management policies because it is a measure of uncertainty. Uncertainty drives
the need for safety inventory to protect against fluctuations in these processes. When
calculating safety inventory, it is necessary to establish an indicator of uncertainty. For
demand forecast, this measure is the Root Mean Squared Error (RMSE). RMSE was used
for two reasons: First, because there is no known consistent forecast bias. Forecast bias is
used here to indicate whether the forecasts are substantially higher or lower than the
actual demands. (Silver, Pyke, & Peterson, 1998) And, second, because RMSE is directly
related to a and can easily be calculated using an Excel spreadsheet (Silver, Pyke, &
Peterson, 1998) to incorporate into an inventory model. In order to calculate the RMSE,
two pieces of raw data* are need:
1. Historical 18 month Rolling Forecast information
2. Historical Monthly Sales data
Once the raw data is gathered and compiled into consistent formats that allow for
comparison, the following process (Silver, Pyke, & Peterson, 1998) is used to calculate
the RMSE:
1. Calculate the demand error. This is the difference between the actual sales for
a given month and the forecasted sales for that month when it was first
included in the frozen period.
i. Ex: Compare January 2009 sales data to the Forecasted January 2009
demand during month of October 2008.
2. Use the RMSE formula to calculate the RMSE for each product.
* All data is analyzed in the unit of measure: Doses. Dose size may vary based on the product; however, for
the purpose of this analysis, it was determined to not be necessary to distinguish this level of detail.
RMSE= .
n
Where e = demand error from step 1 and n = the number of months for which the error was calculated.
Equation 1: Root Mean Squared Error Calculation
3. Once the RMSE data is available, it is important to determine the underlying
distribution of the forecast errors. If they are normally distributed, a set of
readily available formulas can be used within the inventory model. To do this
the following steps were used based on the process for validating normal
probability and Q-Q plots in the book Statistical Methods for Engineers by
Geoffrey Vining (Vining, 1998).
i. The demand error results for an individual product are sorted in
ascending order and assigned a value, i, which is its ranking from 1
through n, where n is the total number of results.
ii. For each error value, a Pi value is calculated:
i - 0.5
Pi= n
Equation 2: P, Value Calculation
iii. Then, using the Pi for each product and the NORMSINV() function in
Microsoft Excel, the Normal Quantile is calculated for each error value.
Table 3 shows an example of the complete set of data needed to produce
the Normal Probability plot.
-208060 1 0,018519 -2,085
-58330 2 0,055556 -1,593
-42630 3 0,092593 -1,325
-38030 4 0,12963 -1,128
-36150 5 0,166667 -0,967
-30800 6 0,203704 -0,828
-29623 7 0,240741 -0,704
-24537 8 0,277778 -0,589
-23450 9 0,314815 -0,482
-21670 10 0,351852 -0,380
Table 3: Sample of Data used for Normal Distribution Test
iv. Using the data in Table 3, the Normal Probability plot is created with the
x-axis as the Error Data and the Y-axis as the Quantile of standard
normal as shown in Figure 5.
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Figure 5: Example Normal Probability Plot
v. The final step is to confirm that the data is normal. This can be done
using the "fat" pencil test, which is performed by imagining laying a
pencil across the data points on the plot to determine if the data is close
to a straight line. If the pencil would cover the majority of the points on
the graph, then it can be concluded that the data is normal (Vining,
1998). The chart in Figure 6 shows data that can be concluded to be
normally distributed.
After completing this analysis for the forecasted demand data, it was determined
that the assumption of a normal distribution is not unreasonable and that the resulting
RMSE measurements can be used in the inventory model's safety stock calculations.
3.3.1.2 Process Flow Lead Times
The next set of data needed as an input for the inventory model is the process flow
lead times. As discussed in Chapter 2, this data exists in a variety of different sources and
at many different levels of data confidence.
... .. ..
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For the Novartis Vaccines inventory model, the process flow was broken into
eight different detailed lead times that roll into four high level lead times and tie directly
to the four main process stages that a product moves through. These lead times are
captured as follows:
1. Concentrate Lead Time
a. Primary Manufacturing process time to achieve Concentrate Material,
including quality requirements
2. Bulk Material Lead Time
a. Primary Manufacturing process time to achieve Bulk Material,
including quality requirements
3. Semi-Finished Lead Time
a. Travel time from Primary Manufacturing Site to Secondary
Manufacturing site, if applicable
b. Secondary Manufacturing Process time to fill material into syringes or
vials, as appropriate, including quality requirements
4. Finished Goods Lead Time
a. Secondary Manufacturing Process time to place product into its final
packaging presentation
b. Batch Release Time
c. Travel time from manufacturing site to customer location
3.3.1.3 Material Value at Each Process Stage
As the material moves through each manufacturing stage, its value increases and
therefore affects decisions one might make regarding what stage to hold the material. At
Novartis Vaccines, the Finance group is responsible for maintaining this information and
providing the necessary data for the inventory model. Table 4 shows a sample of the level
at which the pricing data was collected:
Group 1 0.61 0.70 1.30 1.63 Dose EUROS
Group 2 0.20 0.57 N/A N/A Dose EUROS
Group 3 10.19 38.19 45.00 75.00 Liter EUROS
Group 4 3.72 8.78 10.05 10.56 Dose EUROS
Group 5 211.35 490.06 635.76 672.30 Dose EUROS
Group 6 0.10 0.60 4.30 7.10 Dose EUROS
............................................................... .....................................
Table 4: Sample of Pricing Breakdown by Sub Group
3.4 Data Aggregation
In addition to determining the correct data inputs needed for the model, it is just
as important to identify the optimal hierarchical level at which the model should be built.
Novartis Vaccines has four product franchises that break into approximately 30 product
sub groups which further explode into over 400 SKUs based on country specific
packaging and dosage requirements.
It was clear early on that developing the model at the level of the four franchises
was far too general. This would ignore many of the product nuances that the Production
Logistics planners had identified as critical to making inventory management decisions.
The point of discussion occurred around whether the model should be built at the
individual SKU level or if the product sub groups would provide enough detail to develop
an inventory strategy that consider all the important product characteristics.
As the data and processes became more completely understood, the decision
swung towards aggregating the data at the product sub group level instead of leaving it at
an individual SKU. Aggregation is the concept of pooling demand for several similar
products, which reduces variability because high- and low-demand patterns among
individual products tend to cancel one another; thus yielding a more stable pattern of total
demand (Anupindi, Chopra, Deshmukh, Van Mieghem, & Zemel, 2006). This is
important for the Novartis Vaccines data because the raw data at the product level often
* The data in this table is only provided to represent how cost information was collected and does not
represent actual Novartis Vaccines cost data.
lacked information for certain products which resulted in large fluctuations that were
likely not accurate representations of reality. With the knowledge from the baseline
information gathering, that the demand forecasts have low confidence, it was an ideal
opportunity to use a technique that would allow a reduction in process uncertainty, since
aggregate forecasts are more accurate (Simchi-Levi, Kaminsky, & Simchi-Levi, 2008).
Finally, the availability of the data solidified this approach decision. As data
collection commenced, it became a struggle to find the data at the individual SKU level,
and if it did exist at that level, it was often incomplete. However, obtaining information at
the product sub group level proved to be an easier task.
These factors resulted in the decision to aggregate the data and build the inventory
model at the product sub group level. It is important to note that generally aggregation
groups products that are interchangeable for the purposes of distribution during times of
product shortage. In the case of Novartis, the aggregate groups include products that are
medically similar; however, they may require alternate packaging and labeling depending
on the country of distribution. Thus, the inventory targets within this model are most
appropriate for unpackaged product or product with one common international
packaging.
3.5 Types of Inventory
After defining the key inputs of the model and the level at which the data in the
model exists, one last decision about the approach remained regarding the types of
inventory that should be measured. Based on the product and business characteristics at
Novartis Vaccines, four* types of inventory were identified as critical to inventory
management: Work in Process Inventory, Cycle Inventory, Safety Inventory and
Strategic Inventory. Table 5 defines each type of inventory.
* Seasonal stock, which is another common type of stock, was not included in this model as it is felt that
fluctuations from seasonal demand is sufficiently considered within the other types of stock.
Work in Process Ensures the manufacturing pipeline runs continuously to
meet customer demand.
Cycle Completed on hand inventory that exists due to batch sizing
during the process cycle and to ensure customer demand is
able to be satisfied during that cycle.
Safety Inventory that protects against uncertainty in customer
demand and the manufacturing process.
Strategic Protects against unique attributes in the normal business
environment or within the manufacturing process.
Table 5: Inventory Type Descriptions
(Anupindi, Chopra, Deshmukh, Van Mieghem, & Zemel, 2006)
3.6 Chapter Summary
This Chapter explained the general approach taken to create an inventory policy
for the management of products within Novartis Vaccines' portfolio. Using a two step
approach that combines both unique product business characteristics knowledge as well
as calculates numerical inventory targets offers a balance of subjective and objective
factors that yield an inventory policy that all key stakeholders support. Additionally, the
decision to aggregate the data by product sub group provides a model that is customizable
for each product that is manufactured but is not so detailed that it would be difficult to
sustain the data inputs and thus the quality of the model results.
4 Inventory Model
After setting a clear approach and completing the data collection required for the
inventory analysis, the actual model can be developed using the appropriate inventory
calculations. This Chapter shares the details behind the functionality of the model,
including the methods applied and the special considerations taken due to the company
environment. Additionally, the limitations of the model are discussed. This Chapter also
provides an overview of the results that are generated through the model, which is the
primary source of information that is used for the formal inventory management policy.
4.1 Model Description
As discussed earlier, the inventory model uses a two step approach to determine
the best inventory policy for a sub group. The model considers four process stages
(Concentrate, Bulk, Semi-Finished and Finished Goods) and four inventory types (Work
in Process, Cycle, Safety and Strategic Inventory). Step 1 of the model provides the
inventory strategy for a project and Step 2 uses this strategy to generate actual target
numbers.
4.1.1 Inventory Target Calculations
The second step of the inventory model performs inventory calculations to
determine the targets. The calculations are based on the following formulas and methods.
4.1.1.1 Work in Process Inventory
Work in Process (WIP) inventory is the flow of units being processed in a
manufacturing or service operation (Anupindi, Chopra, Deshmukh, Van Mieghem, &
Zemel, 2006). The calculation used to determine WIP inventory is:
Invetorywip = AverageDailyDemand * ManufacturingStepOperationTime
Equation 3: Work in Process Inventory Calculation
4.1.1.2 Cycle Inventory
Cycle inventory must exist in this model because the process steps are processed
in batches both during production and transportation. Cycle inventory is the average
inventory that arises due to batch activity (Anupindi, Chopra, Deshmukh, Van Mieghem,
& Zemel, 2006). The calculation used to determine cycle inventory is (for the purpose of
this model, the Period equals one month):
InventoryCYCLE = DemandDuringPeriod +2
Equation 4: Cycle Inventory Calculation
4.1.1.3 Safety Inventory
Safety inventories are maintained to protect the process and customers from
unexpected supply disruptions or changes in demand (Anupindi, Chopra, Deshmukh, Van
Mieghem, & Zemel, 2006). The calculation for safety inventory is:
inventorySAFETY = z * RootMeanSquaredError * -LeadTime
Equation 5: Safety Inventory Calculation
(Simchi-Levi, Kaminsky, & Simchi-Levi, 2008)
The Root Mean Squared Error is based on the Demand Forecast accuracy, which
was discussed fully in Section 3.3.1.1. The value of z is the standard normal random
variable based on the Customer Service Level (CSL). CSL is defined as the probability
that there will be no stock outs within an order cycle (one month) (Anupindi, Chopra,
Deshmukh, Van Mieghem, & Zemel, 2006) and is most frequently measured as a
percentage value. An alternative method to measure customer service is by percent
demand satisfied directly from stock; while it is also a percentage value, it is a different
way to measure customer service level. For this inventory model, the first method most
accurately represents how customer service is measured and monitored at Novartis
Vaccines and the inventory model is set up to allow the user to input an appropriate CSL
based on specific service agreements.
4.1.1.4 Strategic Inventory
Strategic inventory protects against unique attributes in the normal business
environment or within the manufacturing process that cannot be incorporated into the
calculations for any of the three previous types of inventory. Within this inventory model,
it is assumed that strategic inventory will be a decision that management makes based on
known product characteristics or future events that would have a large impact on
decisions related to inventory, such as the transition of manufacturing operations from
one facility to another. For this reason, the model is setup to allow the user to input the
specified amount of days of strategic inventory that need to be carried to protect against
the business variations. The resulting calculation for strategic inventory is:
inventorSTRATEGIC = AverageDailyDemand * NumberojDaysoJStrategicCoverage
Equation 6: Strategic Inventory Calculation
4.1.2 Multi-Echelon Inventory Systems
Similar to most other supply chains, the Novartis Vaccines supply chain has
multiple manufacturing steps and process stages that although owned by Novartis, often
occur in different countries and manufacturing facilities. Within supply chain
management, this type of inventory system is commonly referred to as a multi-echelon
inventory system. (Simchi-Levi, Kaminsky, & Simchi-Levi, 2008)
In the Novartis Vaccines supply chain each of the four stages in the process has
its own lead time as well as its own team responsible for monitoring and managing the
process stage. Visibility of inventory levels at all of the locations exists in a single source;
however, past inventory decisions were often made by different levels of management
causing conflict between how each stage was managed and operated.
For a multi-echelon inventory policy to be effective, it is necessary to assume that
(Simchi-Levi, Kaminsky, & Simchi-Levi, 2008):
1. Inventory decisions are made by a single decision maker
2. The decision maker has access to inventory information at each location
Although this has not always been the case at Novartis Vaccines, the move to a single
inventory management policy is aligned with these assumptions and helps to ensure the
policy's success.
4.1.3 Application of Strategic Inventory Placement Model Ideas
The strategic inventory placement (SIP) model was developed by Dr. Stephen
Graves at MIT and is used to determine the amount and positioning of inventories in a
supply chain (Graves & Willems, 2000). Within the inventory model developed for
Novartis Vaccines, principles from the SIP model were applied related to process stage
coupling and lead time calculations. Lead time values were determined based on which
stages inventory is to be held. If inventory is not held at one (or more) stages of the
process, then the associated lead time for that process stage must be accounted for
elsewhere in the inventory calculations, in other words, the two process stages are
coupled. Table 6 shows a simple example of how this works:
Standard Lead Carry Inventory? Adjusted Lead
Stage
Time (Yes/No) Time
1 5 days Yes 5 days
2 5 days No N/A
3 5 days Yes 10 days
4 5 days Yes 5 days
Total 20 days 20 days
Table 6: Lead Time Calculation Example
In this example, since no inventory is carried at Stage 2, the five days of lead time
associated with that stage are coupled with the next stage in the process where inventory
is held. And, safety stock at Stage 3 must cover the increased 10 day lead time. This
results in the same total lead time for the entire process.
When considering whether inventory is held at the final process stage, the
required delivery time to customer must be compared to the actual amount of time it
would take to get the product from its current state to the final state. If that manufacturing
time is greater than the agreed delivery time after an order is placed, then inventory must
be held at the finished goods stage (Graves & Willems, 2000). Although quality
requirements for vaccines often increase standard lead times to many days and even
weeks, the actual manufacturing time for the final two stages within the Novartis
Vaccines process could potentially occur within a single day. Thus, with management's
agreement that this is not a risk, the model allows users to make the decision to not carry
inventory at the finished goods stage.
4.1.4 Periodic Review, Order-Up-To-Level Inventory Model
As discussed earlier in this thesis, Novartis Vaccines has a strong Sales and
Operations Planning process in place that follows a monthly review cycle. This means
that inventory levels, demand forecasts and production plans are reviewed once a month.
This type of regular review is defined as a periodic review system; between each S&OP
process, there is uncertainty related to inventory levels (Silver, Pyke, & Peterson, 1998).
Based on the profile of the Novartis Vaccines supply chain, the inventory model is
structured as a Periodic-Review, Order-Up-To-Level System (R, S). In this type of
system, the control procedure is that every R units of time (for this model, R = 1 month)
an order is placed up to the quantity level of S (Silver, Pyke, & Peterson, 1998). This
inventory model calculates the S value based on the user inputs defined in Chapter 3 and
the formulas explained earlier in this Chapter. Since the calculation for the Order-Up-To-
Level, S, includes all four types of inventory (Work in Process, Cycle, Safety and
Strategic), it incorporates all of the key factors related to the supply chain into the target
inventory level.
4.2 Other Model Considerations
In addition to the standard inventory calculations included in the analytical
inventory model, there are a number of other aspects of the manufacturing process and
products in the Novartis Vaccines environment that need to be incorporated into the
model to ensure completeness: Product Seasonality, Shelf Life, Manufacturing Capacity
Constraints, Batch Sizes and Flexibility for What-If Scenarios.
4.2.1 Product Seasonality
As discussed earlier, the Sales and Operations Planning process runs on a monthly
cycle and produces rolling forecast (RFC) demands for an 18 month period. These rolling
forecasts are actively used by the entire Supply Chain organization for manufacturing,
distribution and warehouse planning. The 18 month demand RFC provides an easy way
for teams to see demand fluctuations and seasonality which exist because of seasonal
illnesses, such as flu in the winter. Or, for products that are geared toward travelers, peak
seasons may exist just before the summer months. These types of fluctuations in demand
can be large and therefore, are critical to the model.
In order to ensure that proper consideration is taken for product seasonality, the
18 month demand RFC is a direct input into the model. All calculations that rely on
average monthly demand are tied directly to the forecast demand for that 18 month
period. This integration into the model allows the user to easily see the impact on
inventory that results from a product's seasonal changes. Additionally, when demand
changes occur, this direct link to the demand data allows for immediate visibility to the
impact that demand change has on the projected inventory levels.
4.2.2 Product Shelf Life
Each product has a different shelf life that must be monitored when product is
stored at each inventory stage. For example, some products cannot be held at a stage for
any longer than 24 hours because of instability in that state. In this case, the business
characteristics analysis allows the model user to clearly input these constraints.
The more complicated aspect of inventory shelf life is ensuring that the inventory
on hand at any given stage does not exceed the expected demand for a product within its
known shelf-life. If this were not checked, a company could be at risk of carrying much
more inventory than can be sold before the product expires. Therefore, within the model,
special logic has been put into place to check the recommended inventory levels against
forecasted demand over the expected shelf life. If the inventory value is greater than
forecasted demand in that period, the model will indicate that the inventory is at risk.
This allows the user the opportunity to modify their inputs and re-run the model or to
move ahead with the knowledge of the risk.
4.2.3 Production Capacity Constraints
All manufacturing operations are limited by their production capability and
vaccine manufacturing is no different. The model is set up to run in its base state
assuming infinite capacity; however, since infinite capacity is not usually realistic, the
user can modify the input sheet to indicate any areas where the recommended inventory
amounts exceed the identified process capacity. The model then uses this data to modify
the Work in Process during any period where capacity is limited and spreads the
inventory required across any periods with excess available capacity. While this is not a
perfect representation of the manufacturing operations at Novartis vaccines, it does offer
a satisfactory way to model how capacity management decisions are made. Thus,
providing a useful tool to help management see how the constraints impact the inventory
plan.
4.2.4 Batch Sizes
Vaccine manufacturing occurs in batch sizes, both during primary and secondary
manufacturing. Although the model is set up to calculate inventory based on doses,
knowledge of batch sizes is important when developing manufacturing plans. Therefore,
the model provides output both in number of doses as well as in number of batches for
each process stage.
4.2.5 Flexibility for What-If Scenarios
Although standard data exists for process lead times, it was determined that
having the ability to change lead times to see the effects on the results would be valuable.
Thus, the model was designed to allow users the ability to change the lead time for an
individual product or even for just a single process step for a given product. The model's
default, however, is to use the standard values. The use of these input fields allows one to
easily perform What-If scenarios and comparisons to understand how a process
improvement or change would impact the inventory levels.
Strategic inventory is also an area where flexibility to input data is useful, and this
too is incorporated in the model. If a step has been identified as requiring strategic
inventory, the user must enter the amount of days of coverage that is required. Again, this
number can easily be changed or removed in order for the user to understand the impacts
to inventory levels.
4.3 Model Limitations
Although the model successfully combines many traditional inventory management
calculations with specific factors related to the Novartis business, the level of
customization leads to the exclusion of other inventory management attributes that should
not be ignored. While many modeling decisions are related to the availability of data, as
has been discussed at points earlier in this chapter, the two limitations identified below
were based primarily on the requirements of the user. However, it is still important to
understand these limitations especially when considering both the results of the model as
well as further opportunities for model improvement.
4.3.1 Individual Process Stage Service Levels
In this inventory model, the customer service level (CSL) used is specific to the
availability of finished goods in the final warehouse. As a result, the safety stock
calculations for each stage use this finished goods CSL. This is a simplification of true
customer service levels. In reality, the service levels of each individual warehouse further
upstream in the process should vary due to process lead time. Fortunately, within
Novartis, the standard CSL that is planned for is 98%, which is shown to not significantly
vary the upstream CSLs (Simchi-Levi, Kaminsky, & Simchi-Levi, 2008). Thus, it is not
unreasonable to exclude this level of detail from the model.
4.3.2 Optimization of Stage Selection
Stage selection for where inventory is to be carried has been set up in this model
in a way that allows the user to drive the results based answers to the Step 1 business
characteristics questions. While this allows the user to understand how business decisions
could impact inventory management, it does not necessarily lead to an optimized
inventory strategy. In order to allow the model to optimize the stage selection, certain
flexibilities that the user requested would need to be removed as well as trust in the raw
data would need to increase.
4.4 Inventory Model Results
As a result of the formulas described above and the other attributes considered in
the model, there are two types of results generated for the user to analyze. The results
from the first step are from the strategic business analysis, which provide the overall
strategy for carrying inventory. From the second step comes the actual inventory target
numbers, which rely on the strategy results from the first step.
4.4.1 Step 1 Output: Business Characteristics Results
In Step 1, the recommended inventory strategy is provided by inventory stage
(Concentrate, Bulk, Semi-Finished and Finished Goods) and by inventory type (Work in
Process, Cycle, Safety and Strategic Inventory). A sample of the output from the model is
shown in Figure 6.
Recommended Stages and Types of Inventory to Hold
Figure 6: Step I Model Results
As indicated above, the results from Step 1 are used as a direct input for Step 2.
4.4.2 Step 2 Output: Analytical Model Results
The analytical model results provide the detailed target numbers that are critical to
setting an inventory management policy. The output sheet provides the following
information and can be seen in full in Appendix 3:
e Average Monthly Inventory Levels for the 18 Month RFC Time Frame
o Averages are shown by inventory type and process stage
e Strategic Inventory Levels for Each Month in the 18 Month RFC Time Frame
e Shelf Life Validation
e Average Monthly Inventory Costs
The results in this output sheet align directly with the variables needed to support a
Period Review, Order-Up-To-Level policy. The average monthly inventory levels in the
output sheet are the values that should be used as the S, or Order-Up-To-Level value.
4.4.3 Chart-Results Output
Although during the course of this project it was not possible to link real time data
with the inventory model to create charts for control and measurement, an output sheet
was developed to provide a visual view of the targets for the next 18 months.
(Additionally, in Chapter 5, there is further discussion about effective ways to establish
real time visibility that would support the inventory model and policy.) There are three
charts, which display the inventory target information as follows:
1. All Up Inventory Targets (Figure 7): This chart shows the total inventory
target for the specific product, both the monthly target value and the
average target value for that 18 month period.
a. There is also an input area that allows the user to manually input the
current Inventory On Hand information in order to see it displayed
on the graph and compare it to the targets.
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Figure 7: Results Chart - All Up Inventory Targets
2. Inventory Targets by Type (Figure 8): This chart also provides both the
monthly and average product inventory targets; however, for the monthly
values, the graph shows the breakdown of inventory type that makes up the
total value.
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Figure 8: Chart Results - Inventory Targets by Type
3. Inventory Targets by Stage (Figure 9): The third chart also displays both
monthly and average inventory targets; however, in this chart, the monthly
targets are broken down by inventory stage instead of type.
a. Additionally, if the user chooses to manually input the current actual
inventory data, this chart is setup to display the current data
compared to the targets by inventory stage.
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Figure 9: Chart Results - Inventory Targets by Stage
With the combination of the detailed data results from Step 2 and the chart results
described here, management and production logistics team members have various ways
to look at the inventory targets and understand the data in order to set a future
manufacturing plan.
4.5 Chapter Summary
This Chapter explains the details of the formulas used to calculate the inventory
targets as well as discusses the special considerations that the model evaluates to ensure
an accurate representation of the Novartis Vaccines environment. The results of the
model were also introduced, offering the first glimpse at what type of information the
user receives from using the model.
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5 Model Implementation and Policy Development
Ensuring continuous use of a new process or model is often the most challenging
aspect of implementing it within an organization. In order to ensure successful integration
within Novartis Vaccines, a formal policy was developed to guide use of the model and
align the new inventory management tool with the Sales & Operations Planning process.
5.1 Sensitivity Analysis
A critical aspect of using the inventory model successfully includes understanding
the different variables that can change and the affect that those changes have on the
resulting inventory targets. This is especially important information when performing
What-If scenarios and evaluating the results from each scenario. Table 7 provides a
summary of the sensitivity for the most critical user variables. See Appendix 4 for an
example of the calculations used to determine model variable sensitivity.
uemana r-orecasi
Accuracy (Root Mean
Squared Error)
High Increases Decreases
Strategic Inventory Days of High Increases Decreases
Coverage
Frozen Period Medium Increases Decreases
Lead Times Medium Increases Decreases
Replensmnt Fequency Medium Decreases Increases
Net inventory quantities do not change, but
Capacity Constraints Low quantities are distributed differently across the
months.
Customer Service Level Low Increases Decreases
Table 7: User Input Variable Sensitivities
5.2 Formal Documentation
Developing only an Excel-based inventory model that performs inventory
analysis does not fully address the challenge of creating a business process for inventory
management. There are many issues related to inventory that cannot be programmed into
an Excel spreadsheet. Additionally, there are many questions that arise regarding how to
manage, monitor and control the inventory model and who is responsible for these tasks.
At Novartis Vaccines and Diagnostics these additional considerations were best
addressed by creating a formal inventory management policy. The policy provides
guidance on how the inventory model should be used to set inventory targets and
provides details related to ensuring that the model is properly sustained to ensure
usefulness for the business not only today but also into the future. In addition to
explaining model functionality, the policy clearly defines the roles and responsibilities of
supply chain personnel as well as the change management process for both the model
itself as well as the targets that result from the model.
Most importantly, the formal policy document provides a single location for
anyone to view the agreed to inventory levels for each sub group. This eliminates
confusion that often results from products being manufactured at multiple sites or
changes in management.
5.3 Inventory Measurement
Following the process and using the model regularly to develop an inventory
strategy and actual targets is a step in the right direction. However, having inventory
targets alone does not provide enough information to make management decisions or to
determine if actual inventory levels are good or bad. Thus, establishing a method to
measure actual inventory levels against the formal targets is a necessity. At Novartis
Vaccines, the use of SAP and Business Warehouse provides a tool that can link the
targets and the actual data. During this project, the different types of measurements
needed were identified; however, the complex business systems work was still required
to complete the link between the two systems.
5.3.1 Use Real Time Visibility to Monitor Current Inventory Performance
By linking the real time data in SAP with the current inventory targets developed
by the inventory model, anyone would have the ability to compare the inventory targets
with current actual inventory levels to determine if there is risk of not meeting the current
months' demand. Figure 10 shows an example of this chart.
Site 1 iSite2 iSite3
mSite4 -Site 5 -+-Targets
Primary
ProductA
Semi-Finished
Product A
Figure 10: Chart of Inventory Targets versus Actual Inventory Levels
In this example, it is evident that this product is at high risk of satisfying demand.
The Finished Goods inventory for both Product AB and AC is well below the targets.
Additionally, early on in the process, at the Primary level, there is no current product in
inventory.
5.3.2 Use Real Time Visibility to Plan for the Future
In addition to monitoring inventory in the current period, it is also useful to
measure the future target projections against the expected future demand and supply
profile. Doing this comparison can help identify potential inventory gaps and help drive
necessary planning changes in order to avoid future problems. In Figure 11, an example
of this chart is shown.
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Figure 11: Chart of Future Inventory Projection Compared to Targets
From this example it can be seen that the product is forecasted to be in a shortage
during the next month. And, with the current planned future production, the actual
inventory levels will be well below the targets.
5.4 Organizational Considerations
Setting up the framework and tools needed to properly manage inventory is often
seen as the most challenging aspect of improving inventory management in an
organization. Any new process or organizational change will not be successful without
fully addressing the impact that it has on the current group members and processes. In the
case of Novartis Vaccines there are four main activities where focus needs to continue
within the organization now that the formal policy is in place:
1. Employee mindset must be consistent with process guidelines and the overall
strategy. The implementation of this new process means that there must be more
value placed on proactive management of inventory versus reactive responses.
Employees at low levels should be willing to add this new tool into their set of
skills and see it as a way to help avoid future challenges not as an added task that
only makes their day busier. Without alignment across all levels of the
organization, the group members will go their own way (Klein, 2004) and, thus,
the likelihood of a successful implementation will decrease.
2. Stakeholders support and encourage the use of the inventory management
process. It is critical that all levels of management have a consistent view on the
value of this new process for managing inventory targets and that they publicly
support and encourage its' use. Stakeholder alignment is critical in creating a
receptive environment for change (Klein, 2004).
3. Integrity of the data used in the inventory management process is constantly
challenged and pushed to be more accurate. A model is only as useful as the
data that is put into it. The current version of the model relies on demand forecasts
that Production Logistics personnel are not sure the accuracy of; increasing
robustness in the demand forecasts will increase trust in the inventory model
results. Additionally, the model relies primarily on manual inputs of the raw data.
Improvement of the use and maintenance of the data in SAP could allow a direct
link between the model and SAP which would help eliminate the risks of data
error due to the manual process.
4. Continuous improvement of the model to allow for increased process
sustainability in the long term. The inventory management policy places
process responsibility in the right role for each product and site. It is critical that
the responsible people update the model as agreed to and actively participate in
providing feedback on how the model could be improved. Continuous
improvement, which is the process of implementing ongoing incremental
improvements in the process (Anupindi, Chopra, Deshmukh, Van Mieghem, &
Zemel, 2006), is an important part of operating as an efficient organization.
5.5 Chapter Summary
Chapter 5 has focused on discussing how the work done in this thesis can be
implemented and sustained throughout a large organization. Considerations include both
business process and organizational structure. The implementation of a formal inventory
management policy shows that the model can be integrated into a policy that can be used
by management to track and measure performance and ultimately to help position the
organization and the company for continued success.
6 Case Studies using the Inventory Model
In order to validate the results of the inventory model as well as demonstrate
model usability for products that face unique inventory management challenges, three
Novartis Vaccines products were analyzed with the inventory model. This Chapter
discusses the challenges faced by each product and how the model was used to help
answer questions and overcome challenges for each product.
6.1 Product 1 Case Study: Setting Targets with High Process
Uncertainty
Product 1 is manufactured at the Marburg, Germany site but is filled and
packaged both in Germany and in Italy. It has a yearly demand in 2010 of approximately
1.5 million vaccines that are to be delivered primarily across North America and Europe.
Product 1 is considered to be a life saving product and thus requires extra emergency
stock to be carried in case of an event that requires a large amount of the vaccine in a
short period of time.
6.1.1 Product 1 Current State
Currently, the product inventory levels and manufacturing production rate is not
at a level that is meeting the required customer demand. This is driven primarily by lower
than expected production yields due to an increase in recent quality issues. Additionally,
the current stock level for Product 1 is much lower than normal as the product was
recently shutdown for three months; therefore, the quality issues arose during the ramp up
period. Furthermore, although there is excess product in storage to prepare for the three
month shutdown, there two problems faced with this stock:
1. In the finished goods state, the product is country specific and cannot be sent to
another country when it has already been packaged in a specific presentation for
the original destination.
2. Although the product shelf-life is four years, the remaining product is less than a
year away from expiration and many customers will not accept it.
These challenges have lead Production Logistics personnel to have to act quickly to try to
secure additional manufacturing time as well as push on Quality Assurance to review the
material failures and help identify solutions that can allow product to be approved for sale
and return the process to its regular performance level.
6.1.2 Product 1 Problem Statement
While the issues of the past cannot be erased, it is important to determine how to
ensure a problem like this does not occur again in the future. Additionally, next year's
capacity is expected to be in far excess of the forecasted 1.5 million doses of demand.
This means that although inventory levels could be built to protect the product from stock
out risk, the question still remains: What are the right levels?
The ideal future state for Product 1 would include a clear strategy for inventory
that considers the current business characteristics and allows for strategy modification as
the product environment changes (in other words, as the process returns to a stable state
when the quality issues are resolved).
6.1.3 Product 1 Analysis
In order to achieve the desired future state for Product 1, the following product
information must be considered and included as user inputs in the inventory model:
e Up to date and accurate demand forecasts,
e Knowledge of available future capacity,
" Understanding of the past process problems, and
* Emergency stock requirements.
Using Step 1 of the model, the key business characteristics of the product were
analyzed. It was determined that the following attributes were necessary for the strategy
and were incorporated into the information input into Step 1:
e Since Product 1 is a life saving product, it is necessary to carry some levels of
Semi-Finished and Finished Goods strategic stock that can quickly be
converted into the required country packaging and delivered in an emergency.
* Inventory cannot be carried at the bulk process stage due to product stability.
" A new facility being built in Marburg could disrupt the concentrate
manufacturing process, which drives the need for strategic stock at that stage.
* The shelf life is high at 4 years, which allows carrying extra stock with low
risk, despite the customer's preference for stock with over 1 year until the
expiration data.
The input of these factors resulted in the strategy for Product 1 as shown in Figure 12.
Recommended Stages and Types of Inventory to Hold
Figure 12: Recommended Inventory Strategy for Product I
Next, these results were used to perform the second step of the inventory model
analysis. For step 2, it was determined that no changes would be made to the standard
information related to Lead Times or Capacity. However, it was desired that there be at
least one year of strategic stock spread across the concentrate, semi-finished and finished
goods stages.
Step 2 of the model was first run using a strategic stock level of one year worth of
demand which lead to the results shown in Table 8.
Avera e Monthi Invento Levels for 18 Month RFC
15,36 58,6 41,5 264
25,641 0 0 2,641
146,299 56,511 41,53 618,763
190,902 56,081 415953 662936
514,979 171,151 1,247,859 1,933,988
Table 8: Product 1 Results, 1 Year Strategic Inventory
Base Stock is equal to WIP stock + Cycle Stock for the given process stage.
Since the results yielded very high numbers, it was necessary to re-run the model using 6
months of demand for strategic inventory. These results were more reasonable (shown in
Table 9), yet still a bit high at approximately 620,000 doses on hand as strategic
inventory and a total of 1.3 million doses on average in any given month.
Average Monthly Inventory Levels for 18 Month RFC
Btlhe 25,641 0 0 25,641
4S s A 146,99 56,51 0,7 410,786
'Fnihe, 6d-:-7r 190,902 56,081 207,976 454,959
oj- aj1 514,979 171,5 623,929 1,310,059
Table 9: Product 1 Result, 6 Months Strategic Inventory
Using these numbers, discussion began about their reasonableness and the
assumptions that were used in the model. Factors that were considered when evaluating
the results were:
" Cost tradeoffs associated with carrying excess product versus losing sales
* The likelihood of exceeding the current demand
e Political impacts that might drive inventory level decisions
" Risk to the market share if the product is not able to be sold
e Actual need for emergency stock
o In Marburg, only 3,500 doses are allocated as emergency stock and
during the month of August 2009, only 3 emergency orders were
placed of quantities of 6, 30 and 85 doses
After considering all of the factors, although the values that resulted with the six
month assumption were higher than expected, it was still at a level that seemed
appropriate. As a result, the best option is to build extra stock today at the six month
level. This will provide protection against uncertain performance as well as known future
production risks, which is very important, based on the recent challenges delivering the
product to customers.
6.2 Product 2 Case Study: Responding to Unexpected Demand
Changes
The second product analyzed using the inventory model is also manufactured at
the Marburg, Germany site. For Product 2, the current forecasted demand for 2010 is
approximately 3.8 million doses split between two different dosages and is primarily
delivered to European countries.
6.2.1 Product 2 Current State
Product 2 currently has inventory levels that are in excess of the projected
demand for 2010. In 2009, Production Logistics executed to a production plan with high
demand projections that had come from Commercial Supply Chain; however, not only
did the forecasted demands decrease gradually in 2009, but even the lowered numbers
were not achieved.
This lead to carrying much higher amounts of inventory than demand requires and
the risk that this material will become obsolete if the demand remains at the current low
level that is forecasted.
6.2.2 Product 2 Problem Statement
Although it is not possible to change the decisions made in the past, the question
posed is how a formal inventory management process or tool could help in scenarios such
as this, when demand forecasts change drastically.
The desired future state for Product 2 is to have a confident demand projection
from the Rolling Forecast, to be able to use market intelligence to evaluate reasonability
of the demand projections and, most importantly, to have a tool that allows management
to see immediately how each new demand forecast impacts the projected inventory
levels.
With the new inventory management policy this can be achieved by using the
inventory model to develop targets in unison with the budgeting process, including
monthly reviews of the projections when each new Rolling Forecast is released to
identify changes early enough to make manufacturing planning changes.
6.2.3 Product 2 Analysis
In order to test the reasonableness of the assumption that the model could help with
responding to large demand changes, a What-If scenario was performed using the 2009
data. The What-If scenario evaluated how the inventory targets would have changed over
the period if the tool were in place.
To be consistent with the inventory management process put in place, the first step
in performing the scenarios was to complete the evaluation of the business characteristics
of the product before performing the iterative analytical model results. The key
characteristics that play into Product 2's inventory management strategy are:
e Strategic inventory was not necessary at any manufacturing stage due to the
extra amounts of inventory that already exist beyond the forecasted demand.
* The past high demand variability made it critical to carry safety stock to
protect against future fluctuations
* No additional inventory beyond Work In Process stock could be carried at
the Bulk stage due to process stability
This resulted in the inventory strategy shown in Figure 13 for Product 2:
Recommended Stages and Types of Inventory to Hold
Figure 13: Recommended Inventory Strategy for Product 2
This information fed into step 2 of the model, where the analytical calculations
are performed to determine the target inventory levels. For the purpose of the analytical
model, no modifications were made to the standard lead times for Product 2; however,
some changes were made to the capacity constraints, which affect how inventory is
spread across the months, but not the average inventory levels.
For this What-If analysis, the most critical input is the 18 month rolling forecast
data which can be used to run the model repeatedly after updating it with each month's
forecast from January 2009 to July 2009. Figure 14 is a chart that shows how the monthly
demand forecasts changed between the months of January, April and July 2009. From the
chart it can be seen that as early as April, the demand forecasts for some months (June
and July) were being greatly reduced. In July, it can be seen that the reductions were
carried forward into the first half of 2010.
1,400,000
1,200,000
1,000,000
600,000
400,000 -
200,000-
Figure 14: Monthly Rolling Forecast for Product 2
As is expected, the results from the inventory model follow the demand forecast
changes for Product 2 and reduce over time. If we isolate the month of July, Table 10
shows how management could have been alerted to a large change in the needed
inventory as early as March when inventory targets reduced by nearly five million doses.
Month Target Was Set In Target For Jul-09
Jan 09 11,849,956
Feb 09 11,826,049
Mar 09 6,861,071
Apr 09 7,091,481
May 09 6,695,047
Jun 09 5,627,778
Table 10: Product 2 Inventory Target Changes for July 2009
Additionally, by combining the inventory target data with actual inventory on
hand data, it is possible to see the differences between what is required to meet customer
demand and the actual inventory on hand for a given month. Figure 15 shows the
inventory on hand level compared to the inventory targets based on the January 2009
RFC versus the July 2009 RFC. It is clear from this figure that inventory levels were
achieved based on the original forecasts; however, they are far off from the changes that
occurred over the months between the January forecast and the actual month of July.
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Figure 15: July Inventory On Hang versus Targets
As a result of this analysis, it is clear that having the ability to forecast inventory
targets as well as update the targets when demands change, could have helped solve the
problems that occurred with the supply planning for Product 2.
6.3 Case Study: Product 3, Using What-If Scenarios to Prepare for the
Future
The third product that was evaluated using the new inventory management process,
Product 3, is manufactured, filled and packaged in Rosia, Italy. The vaccine is distributed
all across the world and as of December 2009, just over 13 million doses are forecasted
for the entire world market during 2010 and the first six months of 2011.
6.3.1 Product 3 Current State
The current inventory levels for Product 3 are at a healthy state based on the
demand and supply activity during 2009; however, in the next 18 months, Product 3 will
be facing very high uncertainty with both demand and supply forecasts.
Although Product 3 has a forecast in place for the next 18 months, this demand
forecast is highly uncertain due to the possibility of Novartis being able to enter the
market of one country in South America for this vaccine. The additional demand for this
market could be either 50,000 or 800,000 doses per month for the product's life. The
current forecast assumes that the upside is achieved, but only through the end of 2010.
In addition to the demand uncertainty, there is also a level of uncertainty related
to supply. This is due to the fact that the contract for a major supplier will be ending and
not renewed in 2010. Although alternative suppliers have been identified, it is uncertain if
they will be qualified and fully up to speed by the time the contract ends. This means that
the total available manufacturing capacity for this vaccine could be a lot less than in past
years.
6.3.2 Product 3 Problem Statement
With this uncertainty for both supply and demand, management needs to answer
two questions:
1. What inventory levels are needed to satisfy both the downside and upside of
the potential future demand for the South American country?
2. How can the potential supply risk be managed to ensure that demand can be
met until a new supplier is onboard?
6.3.3 Product 3 Analysis
Using the inventory model, these questions can be answered by performing What-If
scenarios based on the different possible outcomes. Based on what could occur there are
four outcomes identified that needed to be evaluated, as shown in Figure 16. These four
scenarios along with the base scenario were evaluated in order to help management
understand the different potential outcomes.
SUPPLY
No Change Decrease
SIncrease
lDecrease
Figure 16: Product 3 Demand & Supply Scenarios
Before the detailed analytical calculations could be performed; however, the
business characteristics had to be evaluated. For Product 3, the following product
characteristics were used to complete this step of the inventory analysis:
e No extra bulk inventory carried due to short shelf life during this process stage
* No extra finished goods inventory is carried because the product packaging is
country specific and does not allow for flexibility if order quantities or
destinations change
e Strategic inventory (when needed) is only carried at the concentrate and the semi-
finished good stages
This resulted in the inventory management strategy shown in Figure 17.
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Figure 17: Recommended Inventory Strategy for Product 3
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With this inventory strategy defined, the analytical details could be input to begin
the detailed analysis. In order to perform the What-If scenarios as described, the two
attributes that need to be changed are the demand forecast numbers for the next 18
months and the amount of extra strategic inventory required to ensure that demand during
the months when supply is short is met. In order to perform this analysis, five scenarios
were run:
* Baseline scenario (Table 11): Demand forecast numbers come directly from the
December 2009 rolling forecast and there is no strategic inventory required due to
supply availability risk.
Average Monthly Inventory Levels for 18 Month RFC
# of Days of
values are in doses Base Safety Strategic Total Batches Coverage
2,038,345 28,200 0 2,066,545 1.3 82.1
188,736 0 0 188,736 0.1 7.5
1,308,567 19,059 0 1,327,626 17.7 52.8
75,494 0 0 75,494 1.0 3.0
3,611,142 47,259 0 3,658,401 20.1 145.4
Table 11: Product 4 Inventory Targets - Baseline
* Scenario 1 - Upside scenario with no supply issues (Table 12): The 18 month
rolling forecast demand is increased to assume that the new country requests
800,000 doses per month and there is no strategic inventory required due to
supply availability risk.
Average Monthly Inventory Levels for 18 Month RFC
# of Days of
values are in doses Base Safety Strategic Total Batches Coverage
2,638,345 28,200 0 2,666,545 1.7 81.9
244,291_0 0 244,291 0.2 7.5
1,693,752 19,059 0 1,712,812 22.8 52.6
97,716 0 0 97,716 1.3 3.0
4,674,105 47,259 0 4,721,364 26.0 145.0
Table 12: Product 4 Inventory Targets - Upside
* Scenario 2 - Upside scenario with supply issues (Table 13): The 18 month rolling
forecast demand is increased to assume that the new country requests 800,000
doses per month. Supply constraints begin in 2011; 6 months of strategic
inventory is required to protect during anticipated gap in supply.
Average Monthly Inventory Levels for 18 Month RFC
values are in doses
# of Days of
Base Safety Strategic Total Batches Coverage
2,638,345 28,200 5,862,989 8,529,534 5.3 261.9
244,291 0 0 244,291 0.2 7.5
1,693,752 19,059 5,862,989 7,575,801 101.0 232.6
97,716 0 0 97,716 1.3 3.0
4,674,105 47,259 11,725,979 16,447,343 107.8 505.0
Table 13: Product 4 Inventory Targets - Upside & Supply Risk
Scenario 3 - Downside scenario with no supply issues (Table 14): The 18 month
rolling forecast demand is modified to assume that the new country requests
50,000 doses per month and there is no strategic inventory required due to supply
availability risk.
Average Monthly Inventory Levels for 18 Month RFC
values are in doses
# of Days of
Base Safety Strategic Total Batches Coverage
Concentrate 1,400,845 28,200 0 1,429,045 0.9 82.6
Bulk 129,708 0 0 129,708 0.1 7.5
Semi-Finished 899,308 19,059 0 918,367 12.2 53.1
Finished Goods 51,883 0 0 51,883 0.7 3.0
Total 2,481,744 47,259 0 2,529,003 13.9 146.2
Table 14: Product 4 Inventory Targets - Downside
e Scenario 4 - Downside scenario with supply issues (Table 15): The 18 month
rolling forecast demand is modified to assume that the new country requests
50,000 doses per month. Supply constraints begin in 2011; 6 months of strategic
inventory is required to protect during anticipated gap in supply.
Average Monthly Inventory Levels for 18 Month RFC
# of Days of
values are in doses Base Safety Strategic Total Batches Coverage
Concentrate 1,400,845 28,200 3,112,989 4,542,034 2.8 262.6
Bulk 129,708 0 0 129,708 0.1 7.5
Semi-Finished 899,308 19,059 3,112,989 4,031,356 53.8 233.1
Finished Goods 51,883 0 0 51,883 0.7 3.0
Total 2,481,744 47,259 6,225,979 8,754,982 57.4 506.2
Table 15: Product 4 Inventory Targets - Downside & Supply Risk
These results provide insight into how the inventory targets fluctuate based on the
added demand as well as how adding strategic inventory to the plan can help protect
against future risk and impact the inventory targets.
The final step in evaluating the inventory plan for Product 3 involved looking at
the 5 scenarios side-by-side and considering the key factors to determine which scenario
makes more sense to move forward. Management is able to consider factors such as the
likelihood that the high side demand is really achieved and whether or not the new
supplier will be able to be qualified before the contract for the old supplier ends. In the
end, with high confidence that the demand of 800,000 doses per month would be
achieved and low confidence the new supplier would be onboard in time Scenario 2 -
Upside and Supply Risk was the ideal inventory target plan for 2010.
6.4 Chapter Summary
Throughout this Chapter, we have seen how this inventory model can be applied
to a variety of products with varying challenges. The model has been able to help us
answer questions not only about using the model to set inventory targets, but also allows
us to use the model to run different scenarios when the future is uncertain or there are
different values that may need to be evaluated for a single variable.
7 Conclusions
The previous Chapters in this thesis have explored the environment of an
organization that has high customer service requirements, a very diverse product portfolio
and is still in the early stages of defining business processes. The uniqueness of the
current business environment at Novartis is explored and it was explained how an
inventory model was built to allow for customization and flexibility to fit their
environment. Using three critical products, the model was tested to show that it could be
integrated into the Sales & Operations Planning process and produce usable results.
Finally, a formal policy was put in place to guide the use of the model and to ensure a
process for change control when inventory targets need to be modified. These activities
lead to the successful implementation of not just a tool but a process that can be used to
more effectively manage product inventory.
7.1 Opportunities for Further Research and Process Development
Novartis Vaccines already has a strong Global Supply Chain group that is striving
to put policies in place that support the roles of the people in the organization. Setting up
the inventory management policy is just one step in the right direction. Below are three
areas that need to be focused on to not only offer continuous improvement of the new
inventory management process but also to help future process improvement and
implementation activities.
Further development of the demand forecasting process is necessary. Having a
more robust demand forecasting process and a better way to measure forecast accuracy
would not only help improve the usefulness of the inventory model, but would also help
improve cohesiveness across the supply chain organization. The current process relies
heavily on the knowledge of the commercial sales representatives and allows subjectivity
that causes the Production Logistics personnel to have high levels of doubt in the
forecasts they receive. By implementing a mathematical or statistical method for demand
forecasts, the process could be greatly improved.
Implementing a method to track and monitor planned and actual lead times
throughout all stages of the manufacturing process (including transportation) would help
the organization have a better grasp on where problems are occurring in the process and
where true opportunities for improvement exist. Value Stream Maps* are beginning to be
fully utilized within the Supply Chain group at Novartis Vaccines and these types of tools
are most successful when there is accurate data (including a significant amount of
history) to help evaluate the opportunities for savings.
Finally, Novartis Vaccines would benefit greatly from setting up more formal
process around the use of SAP as well as maintaining the integrity of the data in SAP.
There are many types of information that are currently tracked manually in Excel
spreadsheets that could be maintained by the system. In order to get the most out of
SAP's functionality, the time and effort needs to be made to set it up properly.
Ultimately, it will save a lot more recurring time for supply chain personnel than is
needed for the initial set up.
7.2 Summary of Findings & Recommendations
Based on the lessons learned during the development of this inventory management
policy, there are three key findings that any organization in a similar position must
remember in order to successfully implement an inventory policy:
e Balance analytical considerations with business sense; neither aspect is more or
less important than the other. When setting policies and strategies it is important
that all factors of the business are considered.
" Select the level of data aggregation carefully to ensure consideration of product
specific characteristics yet avoid unnecessary complexity. Each stakeholder is
likely to have a different opinion about what level of data is needed; however,
factors such as the availability of the current data and how performance is
currently measured in the organization must be considered. If a level of detail is
selected that does not fit with the business structure, the tool will not be useful.
Value Stream Maps are a tool to help see and understand the flow of product and material through the
value stream (Rother & Shook, 2003). They are used to help identify waste within the process and develop
improvement ideas to help increase the overall efficiency of the analyzed process.
* Creating an analytical model or business process does not solve the entire
problem related to inventory management. There are many "soft" factors that
need to be considered. Implementations must not happen in a silo and
organizations should not only be aware of the changes, but also have the ability to
provide input in ensuring their success.
In conclusion, it has been shown that the combination of a dynamic model, product
business knowledge and formal processes leads to an inventory policy that not only
provides inventory targets that an organization believes in, but also a process that the
entire team supports.
Appendix 1: Inventory Model Step 1 Input Sheet
Evaluation of Inventory Types and Stages Based on Business Characteristics
Product Name:
Please select use Yes or No to indicate which process stages are required for this product and
where Work in Process (WIP) inventory will exist.
Concentrate No
Bulk No
Semi-Finished No
Finished Goods No
Can you hold extra inventory (above WIP) at each of the following process stages?
Concentrate No
Bulk No
Semi-Finished No
Finished Goods No
Which stage should cycle inventory be carried to protect for demand during the cycle period?
Concentrate No
Bulk No
Semi-Finished No
Finished Goods No
Is the product critical or life savings? No
No
No
No
No
No
No
No
No
No
Is a large amount of demand expected during a time when capacity is limited? NoNo
No
No
No
No
Are anyrgmn of themand currentvery ungtae nedaictye isliitd
No
No
No
No
o~
Appendix 2: Inventory Model Step 2 Input Sheet
Inventory Management Analytical Model
For all boxes colored yellow, please fill in the appropriate Information for that box.
Please select the customer service level that you would like to meet: 98.0%
Inventory Carrying Strategy, based on the results from Step 1. A 1 Indicates Inventory Is carried for that type of material at the given stage, a 0 Indicates Inventory Is not carried at that location.
Work In roiiiesIveltor# 1 1 0 0
cyle I16 sneiory:, 1 0 0 0
MEMI~fflU~iilMIE 1 1 0 0M~iMIliiil!issto1Al~lm 1 0 0 0
Please Indicate the duration of the frozen period for demand forecasts If you would like to use no frozen period for this scenario, please Input 0.
90 |days (assume 30 days per month)
Please indicate the fruency of order replenishment at each process stage. The frequency should be the number of times a month an order/batch can run at that material stage.
Cd066iilM 7 orders/batches that can be run per month8tki il l .M-'lllt 0 orders/batches that can be run per month
hilViniiMill 0 orders/batches that can be run per month
F lii9Ied.1116os 0 orders/batches that can be run per month
If you would like to make modifications to the capacity plan for the next 18 months, click the "+" sign on the left side, otherwise, move onto the next section.
Please use the table below to indicate how annual demand can be filled throughout the year.
A "1" Indicates that monthly demand can be filled as planned, a value less than "1" would Indicate there is less capacity than needed and a value greater than "1" would Indicate
there is more capcI than needed for that months demand. The Total column should always equal 18, but can be dlstrIbuted however Is appmpriate across the month&
MilIMaMMI ||||EeARo ,llA E WiM MMAiO 22001M 21 EUNW10r J YP0Re| AoO1MSU EN01e1 2OI 21e N iiel EME R
Cdntra l 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 10(
BuIl 100% I 100% - 100% 1 100% 100% i100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 10(
SaimiFInlahid", 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 10(
li*.d Goods 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 101
The model will use fixed lead times based on normal operations Please Indicate whether you would like to modify the lead times and input the new lead time for that stage.
Concentrate Material Bulk Material
Standard Lead Time days Standard Lead Time _ _days
Do you want to change the lead time for this material? Do you want to change the lead time for this material?
If yes, please enter the new lead time in days. [ .0J days If yes, please enter the new lead time in days. days
Semi-Finished Finished Goody
Standard Lead Time days Standard Lead Time days
Do you want to change the lead time for this material? Do you want to change the lead time for this material? N
If yes, please enter the new lead time in days. 0.0 days If yes, please enter the new lead time In days. .0 days
For Inventory types that will carry strategic Inventory, please input the amount of coverage (In days) that will be necessary to support this area:
If strategic Inventory will not be carried, please ensure all values for that material type ae 0.
MI E'i !IW llo AN W1 lEW MIA2103 FAPRIMO 9MAY2M1e' .JUNINO3 MODL2NO1 lAUl 106iISM OAwM16 T142fe OiMV)U1 MEim iMM UFm 2Sf"in tItARol1 iAPR
CifiMeintiie 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 1E
RBil @ i 0 0 0 0 0 0 0 0 0 0 : :0 0 0 0 0 0 (
Sain td M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C
Einlie'd!Gdoi 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Appendix 3: Inventory Model Step 2 Output Sheet
17,779,508 4,084,630 41,408,836 63,272,751 192 275.0
10,352,209 3471,880 0 13,824,089 4.2 60.1
0 0 0 0 0.0 0.0
0 0 0 0 0.0 0.0
.1,408,83 41,408,536 41,408,83 41.08,538 41,4083U 41,40,838 41,4U5,38 41408,38 41,U5,M 41,U5,3 41,4UU,838 41,4UU8M 41,4UU,3 41,4U8,38 41,UU,3
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 00 0 0 0 0 0 0 0 0 0 0 0 0 31,880 00 0 0 0 0 0
.................. ..............
Appendix 4: Sensitivity Analysis Details
Testing the sensitivity of Customer Service Level
Original Value 98%
Base Safety Strategic Total
Concentrate 1,742,502 920,517 3,872,226 6,535,245
Bulk 161,343 0 0 161,343
Semi-Finished 882,007 521,526 3,872,226 5,275,759
Finished Goods 64,537 0 0 64,537
Total 2,850,389 1,442,044 7,744,452 12,036,884
Modified Value 99%
Base Safety Strategic Total % Change
Concentrate 1,742,502 1,042,700 3,872,226 6,657,427 1.9%
Bulk 161,343 0 0 161,343 0.0%
Semi-Finished 882,007 590,750 3,872,226 5,344,983 1.3%
Finished Goods 64,537 0 0 64,537 0.0%
Total 2,850,389 1,633,449 7,744,452 12,228,290 1.6%
Modified Value 99.5
Base Safety Strategic Total % Change
Concentrate 1,742,502 1,154,521 3,872,226 6,769,248 1.7%
Bulk 161,343 0 0 161,343 0.0%
Semi-Finished 882,007 654,103 3,872,226 5,408,336 1.2%
Finished Goods 64,537 0 0 64,537 0.0%
Total 2,850,389 1,808,623 7,744,452 12,403,464 1.4%
Modified Value 96%
Base Safety Strategic Total % Change
Concentrate 1,742,502 784,681 3,872,226 6,399,408 -2.1%
Bulk 161,343 0 0 161,343 0.0%
Semi-Finished 882,007 444,567 3,872,226 5,198,800 -1.5%
Finished Goods 64,537 0 0 64,537 0.0%
Total 2,850,389 1,229,247 7,744,452 11,824,088 -1.8%
Testing the Sensitivity of the Frozen Period
Original Value
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
Modified Value
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
15 days
Base Safety Strategic Total
1,742,502 920,517 3,872,226 6,535,245
161,343 0 0 161,343
882,007 521,526 3,872,226 5,275,759
64,537 0 0 64,537
2,850,389 1,442,044 7,744,452 12,036,884
90 days
Base Safety Strategic Total %Change
1,742,502 920,517 3,872,226 6,535,245 0.0%
968,057 0 0 968,057 500.0%
882,007 521,526 3,872,226 5,275,759 0.0%
64,537 0 0 64,537 0.0%
3,657,102 1,442,044 7,744,452 12,843,598 6.7%
Modified Value 30 days
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
Base Safety Strategic
1,742,502 920,517 3,872,226
322,686 0 0
882,007 521,526 3,872,226
64,537 0 0
3,011,731 1,442,044 7,744,452
Total %Change
6,535,245 0.0%
322,686 100.0%
5,275,759 0.0%
64,537 0.0%
12,198,227 1.3%
Testing the Sensitivity of Order Replenishment
Original Value
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
Modified Value
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
Modified Value
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
Modified Value
Concentrate
Bulk
Semi-Finished
Finished Goods
Total
all at I per month
Base Safety Strategic Total
1,742,502 920,517 3,872,226 6,535,245
645,371 0 0 645,371
1,462,841 744,607 3,872,226 6,079,674
645,371 0 0 645,371
4,496,085 1,665,125 7,744,452 13,905,661
all at 4 times per month
Base Safety Strategic Total %Change
1,258,473 782,289 3,872,226 5,912,989 -9.5%
161,343 0 0 161,343 -75.0%
978,813 564,858 3,872,226 5,415,897 -10.9%
161,343 0 0 161,343 -75.0%
2,559,972 1,347,147 7,744,452 11,651,571 -16.2%
all at 10 times per month
Base Safety Strategic
1,161,668 751,599 3,872,226
161,343 0 0
882,007 521,526 3,872,226
64,537 0 0
2,269,555 1,273,125 7,744,452
Total % Change
5,785,493 -11.5%
161,343 -75.0%
5,275,759 -13.2%
64,537 -90.0%
11,287,132 -18.8%
all at 30 times per month
Base Safety Strategic Total %Change
1,118,643 737,549 3,872,226 5,728,419 -12.3%
161,343 0 0 161,343 -75.0%
838,982 501,066 3,872,226 5,212,274 -14.3%
21,512 0 0 21,512 -96.7%
2,140,480 1,238,616 7,744,452 11,123,548 -20.0%
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